GlassScriptPhysician profile
Jean Claude Stephan Andre
NPI 1932348562
$1,854.20
in general payments reported to CMS, 2019-2025
14 companies · $685 in 2025
The $685 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $61.35 · 2021: $134 · 2022: $152 · 2023: $151 · 2024: $670 · 2025: $685.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,507.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,506.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $379.44 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $277.81 | 2024-2025 | Zerbaxa, Dificid, Capvaxive |
| Janssen Pharmaceuticals, INC | $269.25 | 2020-2024 | Xarelto |
| Melinta Therapeutics, LLC | $235.93 | 2023-2025 | Kimyrsa, Rezzayo, Orbactiv |
| Shionogi INC | $173.68 | 2024-2025 | Fetroja |
| Abbott Laboratories | $140.76 | 2024 | Optis |
| Pfizer INC. | $100.03 | 2021-2023 | |
| E.R. Squibb & Sons, L.L.C. | $77.83 | 2020-2025 | Eliquis |
| Gilead Sciences, INC. | $64.28 | 2023-2025 | Yeztugo |
| La Jolla Pharmaceutical Company | $60.50 | 2025 | Xacduro, Zevtera |
| Reprise Biomedical, INC. | $23.46 | 2023 | Miro3d |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.75 | 2025 | Jardiance |
| Smith+Nephew, INC. | $16.31 | 2024 | Collagenase Santyl |
| Allergan, INC. | $13.17 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jean Andre listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.